Revenue
$37.67M
Fiscal year ended 2026-06-30Operating income
-$2.04M
Fiscal year ended 2026-06-30Free cash flow
-$2.35M
Fiscal year ended 2026-06-30HERON THERAPEUTICS, INC. /DE/ (HRTX) reported revenue of $37.67M and net income of -$5.49M for the fiscal year ended 2026-06-30. This page shows 10 annual periods of income statement, balance sheet and cash flow figures normalized from HERON THERAPEUTICS, INC. /DE/’s SEC filings, each linked to the filing it came from. It is classified by the SEC under Pharmaceutical Preparations.
Income
| Metric | 2026-06-30 | 2026-03-31 | 2025-12-31 | 2025-09-30 | 2025-06-30 | 2025-03-31 | 2024-12-31 | 2024-09-30 | 2024-06-30 | 2024-03-31 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $37.67M | $34.71M | $40.59M | $38.21M | $37.20M | $38.90M | $40.78M | $32.81M | $36.02M | $34.67M |
| Cost of revenue | $11.57M | $10.64M | $11.12M | $11.91M | $9.86M | $8.46M | $10.23M | $9.46M | $10.52M | $8.44M |
| Gross profit | $26.09M | $24.07M | $29.47M | $26.30M | $27.34M | $30.45M | $30.55M | $23.35M | $25.51M | $26.23M |
| Operating income | -$2.04M | -$4.76M | $38.00K | -$4.09M | -$1.64M | $3.15M | $4.17M | -$4.46M | -$6.44M | -$4.80M |
| Net income | -$5.49M | -$8.11M | -$2.95M | -$17.50M | -$2.38M | $2.64M | $3.66M | -$4.85M | -$9.24M | -$3.16M |
| Research & development | $2.70M | $2.38M | $3.75M | $3.47M | $2.93M | $2.28M | $3.18M | $4.46M | $4.43M | $4.61M |
| Weighted-average diluted shares | shares 190.34M | shares 189.65M | Unavailable | shares 170.35M | shares 154.02M | shares 196.92M | Unavailable | shares 152.83M | shares 152.30M | shares 151.20M |
| Pretax income | Unavailable | Unavailable | Unavailable | Unavailable | Unavailable | Unavailable | Unavailable | Unavailable | Unavailable | Unavailable |
| Income tax expense | Unavailable | Unavailable | Unavailable | Unavailable | Unavailable | Unavailable | Unavailable | Unavailable | Unavailable | Unavailable |
| Diluted EPS | $-0.03 | $-0.04 | Unavailable | $-0.10 | $-0.02 | $0.01 | Unavailable | $-0.03 | $-0.06 | $-0.02 |
| Selling, general & administrative | $25.44M | $26.45M | $25.68M | $26.92M | $26.05M | $25.01M | $23.20M | $23.34M | $27.52M | $26.42M |
| General & administrative | $11.28M | $12.14M | $13.45M | $13.98M | $14.47M | $12.70M | $12.14M | $12.37M | $13.90M | $14.97M |
| Selling & marketing | $14.16M | $14.31M | $12.23M | $12.94M | $11.58M | $12.31M | $11.06M | $10.97M | $13.61M | $11.44M |
Balance
| Metric | 2026-06-30 | 2026-03-31 | 2025-12-31 | 2025-09-30 | 2025-06-30 | 2025-03-31 | 2024-12-31 | 2024-09-30 | 2024-06-30 | 2024-03-31 |
|---|---|---|---|---|---|---|---|---|---|---|
| Cash & equivalents | $20.72M | $26.12M | $28.65M | $43.07M | $16.52M | $19.27M | $25.80M | $25.74M | $18.39M | $20.45M |
| Total assets | $252.26M | $246.22M | $255.88M | $248.95M | $232.09M | $235.75M | $233.15M | $220.78M | $218.14M | $217.89M |
| Current assets | $229.84M | $228.98M | $238.07M | $229.40M | $210.92M | $212.84M | $209.01M | $195.19M | $191.17M | $185.90M |
| Total liabilities | $245.35M | $237.08M | $241.54M | $234.06M | $259.35M | $264.20M | $266.80M | $260.78M | $256.08M | $251.65M |
| Current liabilities | $92.14M | $90.52M | $96.10M | $89.71M | $258.60M | $88.56M | $91.46M | $85.54M | $80.32M | $75.38M |
| Total equity incl. NCI | $6.91M | $9.14M | $14.33M | $14.88M | -$27.26M | -$28.45M | -$33.65M | -$40.00M | -$37.94M | -$33.77M |
| Temporary (mezzanine) equity | Unavailable | Unavailable | Unavailable | Unavailable | Unavailable | Unavailable | Unavailable | Unavailable | Unavailable | Unavailable |
| Inventory | $90.58M | $92.54M | $92.75M | $70.02M | $72.96M | $56.93M | $53.16M | $45.95M | $42.86M | $42.47M |
| Accounts receivable | $89.57M | $83.69M | $89.59M | $81.05M | $79.93M | $78.74M | $78.88M | $67.04M | $73.71M | $65.32M |
| Goodwill | Unavailable | Unavailable | Unavailable | Unavailable | Unavailable | Unavailable | Unavailable | Unavailable | Unavailable | Unavailable |
| Long-term debt | Unavailable | Unavailable | Unavailable | Unavailable | Unavailable | Unavailable | Unavailable | Unavailable | Unavailable | Unavailable |
| Accounts payable | $11.64M | $8.97M | $8.99M | $12.02M | $12.04M | $12.33M | $11.71M | $10.19M | $10.23M | $837.00K |
Cash flow
| Metric | 2026-06-30 | 2026-03-31 | 2025-12-31 | 2025-09-30 | 2025-06-30 | 2025-03-31 | 2024-12-31 | 2024-09-30 | 2024-06-30 | 2024-03-31 |
|---|---|---|---|---|---|---|---|---|---|---|
| Operating cash flow | -$2.21M | -$1.54M | -$9.18M | $1.33M | -$10.87M | -$8.87M | -$11.78M | $3.37M | -$4.60M | -$9.52M |
| Capital expenditures | $138.00K | $391.00K | $0 | $0 | $208.00K | $109.00K | $638.00K | $431.00K | Unavailable | Unavailable |
| Investing cash flow | -$3.26M | -$939.00K | -$5.46M | $11.86M | $7.33M | $2.27M | $11.42M | $3.97M | $2.05M | $1.28M |
| Financing cash flow | $82.00K | -$51.00K | $219.00K | $13.36M | $781.00K | $64.00K | $423.00K | $14.00K | $492.00K | $11.00K |
| Net change in cash | -$5.40M | -$2.53M | -$14.42M | $26.55M | -$2.75M | -$6.53M | $61.00K | $7.36M | -$2.06M | -$8.23M |
| Stock-based compensation | $3.18M | $2.98M | $2.18M | $2.85M | $2.80M | $2.51M | $2.30M | $2.72M | $4.57M | $3.38M |
| Common dividends paid | Unavailable | Unavailable | Unavailable | Unavailable | Unavailable | Unavailable | Unavailable | Unavailable | Unavailable | Unavailable |
| Common share repurchases | Unavailable | Unavailable | Unavailable | Unavailable | Unavailable | Unavailable | Unavailable | Unavailable | Unavailable | Unavailable |
| Depreciation & amortization | $452.00K | $529.00K | $537.00K | $615.00K | $611.00K | $551.00K | $581.00K | $581.00K | $641.00K | $689.00K |
Derived
| Metric | 2026-06-30 | 2026-03-31 | 2025-12-31 | 2025-09-30 | 2025-06-30 | 2025-03-31 | 2024-12-31 | 2024-09-30 | 2024-06-30 | 2024-03-31 |
|---|---|---|---|---|---|---|---|---|---|---|
| Free cash flow | -$2.35M | -$1.93M | -$9.18M | $1.33M | -$11.08M | -$8.98M | -$12.42M | $2.94M | Unavailable | Unavailable |
| Gross margin | 69.3% | 69.4% | 72.6% | 68.8% | 73.5% | 78.3% | 74.9% | 71.2% | 70.8% | 75.6% |
| Operating margin | -5.4% | -13.7% | 0.1% | -10.7% | -4.4% | 8.1% | 10.2% | -13.6% | -17.9% | -13.8% |
| FCF margin | -6.2% | -5.6% | -22.6% | 3.5% | -29.8% | -23.1% | -30.5% | 9.0% | Unavailable | Unavailable |
| SBC / revenue | 8.4% | 8.6% | 5.4% | 7.5% | 7.5% | 6.5% | 5.6% | 8.3% | 12.7% | 9.7% |
| Current ratio | 2.49x | 2.53x | 2.48x | 2.56x | 0.82x | 2.40x | 2.29x | 2.28x | 2.38x | 2.47x |
| Revenue YoY growth | 1.3% | -10.8% | -0.5% | 16.5% | 3.3% | 12.2% | 19.1% | 4.4% | 13.4% | 17.1% |
| Net margin | -14.6% | Unavailable | -7.3% | -45.8% | -6.4% | Unavailable | 9.0% | -14.8% | Unavailable | Unavailable |
| R&D / revenue | 7.2% | 6.9% | 9.2% | 9.1% | 7.9% | 5.9% | 7.8% | 13.6% | 12.3% | 13.3% |
| CapEx / revenue | 0.4% | 1.1% | 0.0% | 0.0% | 0.6% | 0.3% | 1.6% | 1.3% | Unavailable | Unavailable |
| Long-term debt / equity | Unavailable | Unavailable | Unavailable | Unavailable | Unavailable | Unavailable | Unavailable | Unavailable | Unavailable | Unavailable |
| Effective tax rate | Unavailable | Unavailable | Unavailable | Unavailable | Unavailable | Unavailable | Unavailable | Unavailable | Unavailable | Unavailable |
Amounts are abbreviated; the exact reported value is carried in each cell. — means unavailable, not zero. Open HRTX in the interactive workspace to inspect any figure back to its filing.
Source filings
10-Q · Filed 2026-08-10View SEC filing
10-Q · Filed 2026-05-11View SEC filing
10-K · Filed 2026-02-26View SEC filing
10-Q · Filed 2025-11-04View SEC filing
10-Q · Filed 2025-08-08View SEC filing
10-Q · Filed 2025-05-06View SEC filing
Every accounting identity this site checks — the balance sheet, the gross profit bridge and the cash flow statement — reconciles in every period shown.